Heart transplantation for dilated cardiomyopathy

Area of Science:

• Pediatric Cardiology
• Cardiovascular Surgery
• Immunology

Background:

• Dilated cardiomyopathy is a significant cause of heart failure in children.
• Advanced medical management often proves insufficient for pediatric patients with end-stage heart disease.
• Heart transplantation is a potential life-saving intervention for eligible pediatric candidates.

Purpose of the Study:

• To evaluate the efficacy and outcomes of heart transplantation in pediatric patients with dilated cardiomyopathy.
• To assess the short-term survival rates and complications following heart transplantation in this cohort.
• To determine the suitability of heart transplantation as a therapeutic option for pediatric dilated cardiomyopathy.

Main Methods:

• A retrospective analysis of 23 pediatric patients (8 months to 16 years) who underwent heart transplantation between 1988 and 1994.
• Patients selected based on failure to thrive or inotrope dependence despite maximal medical therapy.
• Standard immunosuppression regimen included cyclosporine, azathioprine, and prednisolone.

Main Results:

• The mean age of patients was 7.1 years, with diverse etiologies of cardiomyopathy including idiopathic, congenital, and anthracycline-induced.
• Mean waiting time for transplantation was 22 days.
• Actuarial survival rates were 95% at one year and 87% at three years post-transplantation.
• Four patients developed coronary artery disease, with one mortality attributed to this complication 15 months post-transplant.

Conclusions:

• Heart transplantation is an acceptable short-term therapeutic option for pediatric patients with dilated cardiomyopathy.
• While effective, long-term complications such as coronary artery disease require ongoing monitoring.
• This study highlights the potential of heart transplantation to improve survival in critically ill pediatric cardiac patients.